Used in targeted cancer therapy, particularly for solid tumors and hematologic malignancies. Binds selectively to the TWEAK receptor (TNFRSF12A), which is overexpressed in certain cancer cells, triggering apoptosis and inhibiting tumor growth. Investigated for its role in enhancing the immune system’s ability to recognize and destroy cancer cells, especially in combination with other immunotherapies. Also explored in autoimmune and inflammatory diseases due to its modulation of inflammatory signaling pathways. Currently in experimental and clinical trial stages to evaluate safety, efficacy, and optimal dosing regimens.